Biotech stocks with the lowest price to sales ratio

Ranked

63

of 146 biotech stocks we cover

Median

6.5×

Lowest

0.2×

CRIS

Range

0.2× to 87.7×

#	Company	P/S	Net margin	Revenue growth (TTM)	Market cap
1	CRISCuris	0.2×	n/m	−62.2%	$807.4K
2	SCLXScilex	0.6×	n/m	−28.5%	$20M
3	CSBRChampions Oncology	1.1×	−1.8%	+6.7%	$65.7M
4	PTHSPelthos Therapeutics	1.5×	n/m	n/m	$65.1M
5	TCRXTScan Therapeutics	1.9×	n/m	+2.2%	$13.8M
6	BCRXBiocryst Pharmaceuticals	2.1×	−40.9%	+68.7%	$2B
7	AGENAgenus	2.1×	69.3%	+30.5%	$285M
8	MGTXMeiraGTx	2.2×	19.9%	n/m	$884.6M
9	RGNXREGENXBIO	2.5×	n/m	+12.0%	$441M
10	PLXProtalix BioTherapeutics	2.5×	23.5%	+30.1%	$205.5M
11	ELUTElutia	3.1×	n/m	−18.2%	$37.1M
12	CHRSCoherus Oncology	3.1×	n/m	+61.0%	$156M
13	IVVDInvivyd	3.1×	n/m	+26.3%	$180.8M
14	VYGRVoyager Therapeutics	3.1×	n/m	−19.1%	$107.2M
15	STROSutro Biopharma	3.4×	n/m	−56.3%	$154.7M
16	AUTLAutolus Therapeutics	3.5×	n/m	+292.2%	$409.9M
17	IMCRImmunocore	3.7×	−4.2%	+21.0%	$1.6B
18	DYAIDyadic International	3.8×	n/m	−8.0%	$14.5M
19	NVAXNovavax	3.9×	−59.9%	−61.6%	$1.6B
20	INCYIncyte	4.0×	27.7%	+26.9%	$23.5B
21	DTILPrecision Biosciences	4.1×	n/m	n/m	$183.3M
22	NBIXNeurocrine Biosciences	4.3×	20.9%	+34.4%	$14.5B
23	LENZLENZ Therapeutics	4.6×	n/m	n/m	$99.3M
24	ADMAAdma Biologics	4.7×	33.0%	+8.0%	$2.4B
25	TARSTarsus Pharmaceuticals	4.9×	−7.7%	+105.2%	$3B
26	REGNRegeneron Pharmaceuticals	5.3×	27.9%	+9.3%	$82.9B
27	CRBUCaribou Biosciences	5.7×	n/m	+10.0%	$57.1M
28	VIRVir Biotechnology	5.9×	−83.0%	n/m	$1.8B
29	FENCFennec Pharmaceuticals	6.0×	−5.5%	+77.8%	$353.5M
30	DNAGinkgo Bioworks	6.0×	n/m	−46.8%	$672.7M
31	ALNYAlnylam Pharmaceuticals	6.2×	16.8%	+95.1%	$30B
32	FDMT4D Molecular Therapeutics	6.5×	n/m	n/m	$596.6M
33	EXELExelixis	6.6×	35.3%	+9.2%	$16B
34	ONCBeOne Medicines	7.0×	10.7%	+34.3%	$42.9B
35	VCELVericel	7.1×	7.9%	+23.0%	$2.2B
36	EDITEditas Medicine	7.8×	n/m	+20.8%	$368.6M
37	UTHRUnited Therapeutics	8.0×	41.6%	+2.5%	$25.2B
38	HALOHalozyme Therapeutics	8.6×	24.9%	+41.2%	$14.3B
39	TECHBIO-TECHNE	9.4×	15.0%	−0.4%	$11.4B
40	VRTXVertex Pharmaceuticals	10.6×	35.0%	+10.2%	$132.8B
41	CCCCC4 Therapeutics	10.7×	n/m	+2.3%	$376.5M
42	ACOGAlpha Cognition	11.9×	n/m	n/m	$181.6M
43	PLURPluri	12.0×	n/m	−24.0%	$12.2M
44	RGENRepligen	12.7×	5.3%	+16.5%	$10B
45	ADPTAdaptive Biotechnologies	13.2×	−20.7%	+50.1%	$4.1B
46	ALECAlector	14.7×	n/m	−82.9%	$204.3M
47	BEAMBeam Therapeutics	15.9×	−54.7%	+158.9%	$2.5B
48	INSMInsmed	17.9×	−76.9%	+185.8%	$20.4B
49	LCTXLineage Cell Therapeutics	19.3×	n/m	+19.9%	$252.9M
50	IOVAIovance Biotherapeutics	19.6×	−89.1%	+34.5%	$6.4B
51	VIVSVivoSim Labs, INC.	19.7×	n/m	−21.1%	$2.2M
52	XFORX4 Pharmaceuticals	20.3×	n/m	−51.6%	$321.2M
53	TWSTTwist Bioscience	20.3×	−31.7%	+19.2%	$8.8B
54	KRYSKrystal Biotech	20.9×	54.8%	+22.6%	$9.2B
55	SRZNSurrozen	26.0×	n/m	−8.8%	$299.5M
56	GLUEMonte Rosa Therapeutics	32.2×	n/m	−83.9%	$924.8M
57	MRNAModerna	35.9×	n/m	−27.6%	$79.9B
58	RXRXRecursion Pharmaceuticals	36.1×	n/m	−15.1%	$2B
59	FATEFate Therapeutics	38.9×	n/m	−23.4%	$252.8M
60	AIMAIM ImmunoTech	50.1×	n/m	−21.5%	$4.8M
61	IBRXImmunityBio	52.5×	n/m	+192.9%	$8.7B
62	HUMAHumacyte	57.0×	n/m	+159.3%	$121M
63	KYMRKymera Therapeutics	87.7×	n/m	+134.8%	$9.2B

Not ranked: 31 with not a meaningful number, 16 with a quarter missing, 7 with a value too high to mean anything, 3 with a value above 100× (too small a base to compare), 3 with no price to sales (not meaningful for banks and some insurers). 23 companies whose data behind this number has a caveat are left out until it is checked.

A ranking of numbers, not a recommendation. A low multiple can be a bargain or a business in trouble: open the company to see which.